[{"name":"Case Discussion: Medical Need for Novel HER2-Directed Options After Failure on Standard-of-Care Treatments (ID 838)","mode":"","is_cme":false,"info":{"presentation":"Case Discussion: Medical Need for Novel HER2-Directed Options After Failure on Standard-of-Care Treatments <small>(ID 838)<\/small>","session":"CME Webinar Supported by Daiichi Sankyo - Industry Satellite Symposium: Novel Therapies for Relapsed or Refractory HER2- Positive Metastatic Breast Cancer <small>(ID 83)<\/small>","presenter":"Thomas Bachelot<small> (Lyon, France)<\/small>","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/breast2020\/persons\/photos\/49.jpg"},"playlist":[{"name":"Case Discussion: Medical Need for Novel HER2-Directed Options After Failure on Standard-of-Care Trea","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/83\/v\/838_1c.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/breast2020\/83\/v\/838_1c.mp4","cover":"","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/83\/v\/838_1c.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/83\/v\/838_1c-thumbnails.vtt"}]}]{"provider":"CTI","provider_live":0,"type":1,"code":"9L240fs02Vk"}